| abstract |
FIELD: medicine. n SUBSTANCE: invention refers to medicine and represents a method for preparing a therapeutic radioconjugate of a specifically binding agent with a short-lived radionuclide for the delivery to pathological regions. Implementing the method involves labelling recombinant humanised mini-antibodies specific to the cancer-associated antigen HER2/neu, with the diagnostic gamma-ray radionuclide aquacarbonyl complex Tc-99m; the mini-antibodies are conjugated with human albumin; the prepared conjugate is purified and added with the chelating agent DOTA (1,4,7,10-tetraazacyclododecane tetraacetic acid) or DTPA (diethylene triamine pentaacetic acid); the prepared conjugate is labelled with the therapeutic alpha-ray radionuclides; and the produced preparation is purified. n EFFECT: producing the anti-cancer preparation possessing a low risk of the conflict with the immune system, simplifying the formulation and providing a demand for preparations with targeted agent delivery. n 6 cl, 1 dwg, 1 ex |